Novel Antidepressants

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published September 3, 2026•Updated September 3, 2026•Reviewed September 3, 2026

Indications

Primary Indications

Treatment-resistant depressionMajor depressive disorderAcute suicidalityBipolar depression (investigational)

Mechanism

Novel antidepressants employ diverse mechanisms beyond monoamine reuptake inhibition. Examples: NMDA antagonists (esketamine, ketamine), GABA-A receptor positive modulators (zuranolone), NMDA partial agonists (rapastinel), AMPA potentiators, and kappa-opioid receptor antagonists. Many also influence neurotrophic signaling (e.g., BDNF), supporting neuroplasticity and resilience.

Protocol

Preparation

Comprehensive psychiatric evaluation, cardiovascular screening if relevant, and medication review.

Procedure

Oral daily dosing (zuranolone, investigational agents).
Intranasal esketamine administered under supervision in clinic.
IV infusion protocols for ketamine or trial drugs.

Frequency: Daily or intermittent dosing depending on compound.

Duration: Acute treatment 2–6 weeks; maintenance schedules being studied.

Total Treatment Time: Variable by compound and indication.

Expected Outcomes

Immediate

Symptom relief within hours to days for some agents

Short Term

Improved mood and functioning
Reduction in suicidality

Long Term

Sustained remission possible with maintenance
Durability varies by compound

Side Effects

common

Sedation
Dissociation (for NMDA agents)
Headache
Nausea

uncommon

Dizziness
Transient anxiety
Cognitive blunting

rare

Abuse liability (NMDA agents)
Withdrawal with abrupt discontinuation

Contraindications

absolute

Severe uncontrolled medical illness
Pregnancy (neurosteroids)
Active psychosis (glutamatergic drugs)

relative

History of substance misuse
Liver impairment

special considerations

Monitoring required for dissociative or sedative side effects

Research Evidence

Key Studies

Daly EJ et al., 'Efficacy of intranasal esketamine in TRD', JAMA Psychiatry (2019).
Gunduz-Bruce H et al., 'Trial of SAGE-217 (zuranolone) in major depressive disorder', NEJM (2019).
Preskorn SH et al., 'Rapastinel: an investigational NMDA receptor modulator in MDD', J Clin Psychiatry (2015).

Limitations

Durability of effect uncertain; some trials show high placebo response; long-term safety not fully characterized.

Cost Considerations

typical session cost: $600–$900 for esketamine; oral agents may be less expensive once approved

total treatment cost: Highly variable; insurance coverage emerging for FDA-approved drugs

insurance coverage: Esketamine and zuranolone may be covered; investigational agents typically out-of-pocket

cost effectiveness: Potentially high if rapid remission reduces hospitalization and disability

ux display: undefined

collapsible: undefined

heading: undefined

Integration Support

Concurrent Therapies

Psychotherapy
Ongoing antidepressant therapy
Lifestyle and social support

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists